An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s73, 2020. DOI: 10.25251/skin.4.supp.73. Disponível em: https://jofskin.org/index.php/skin/article/view/1106. Acesso em: 22 jul. 2024.